The great divide? The interaction of patent law and antitrust in the pharmaceutical markets

2 minutes de lecture
12 août 2021


For decades now the fault line between patent law and competition law has given rise to friction and a lot of litigation. The divide still exists, and over the last decade the competition authorities have moved into the space to conduct their own investigations to consider whether patent ownership gives rise to anti-competitive behaviour.

Is that right? Does the patent system itself already provide all the necessary checks and balances to govern the competition issues without external interference which might damage the delicate balance by which the existence of enforceable IP rights incentivises investment in research and development?

In his article 'The Great Divide? The interaction of patent law and antitrust in the pharmaceutical markets', first published in the BIO-Science Law Review, IP partner Gordon Harris looks at the position and concludes that the patent system is capable of policing itself.

Gordon's career in IP started in this arena with the "Car Parts Wars" of the 80s and 90s. He conducted the leading case, Veng v Volvo in the European Court of Justice (as it was then known) and has always maintained an interest in this key question.

*This article was first published in the BIO-Science Law Review

CECI NE CONSTITUE PAS UN AVIS JURIDIQUE. L'information qui est présentée dans le site Web sous quelque forme que ce soit est fournie à titre informatif uniquement. Elle ne constitue pas un avis juridique et ne devrait pas être interprétée comme tel. Aucun utilisateur ne devrait prendre ou négliger de prendre des décisions en se fiant uniquement à ces renseignements, ni ignorer les conseils juridiques d'un professionnel ou tarder à consulter un professionnel sur la base de ce qu'il a lu dans ce site Web. Les professionnels de Gowling WLG seront heureux de discuter avec l'utilisateur des différentes options possibles concernant certaines questions juridiques précises.